Mass eradication of Helicobacter pylori: feasible and advisable?

Lancet. 2011 Aug 6;378(9790):462-4. doi: 10.1016/S0140-6736(11)61099-4. Epub 2011 Jul 21.

Authors

Luiz Edmundo Mazzoleni¹, Carlos Fernando Francesconi, Guilherme Becker Sander

Affiliation

¹ Universidade Federal do Rio Grande do Sul, School of Medicine, Porto Alegre, Brazil. lemazzoleni@yahoo.com.br

PMID: 21777975
DOI: 10.1016/S0140-6736(11)61099-4

No abstract available

Publication types

Comment

MeSH terms

2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage
Amoxicillin / administration & dosage
Amoxicillin / adverse effects
Anti-Bacterial Agents / administration & dosage*
Anti-Bacterial Agents / adverse effects
Clarithromycin / administration & dosage
Clarithromycin / adverse effects
Drug Administration Schedule
Drug Therapy, Combination
Drugs, Generic
Feasibility Studies
Female
Health Policy / trends*
Helicobacter Infections / drug therapy*
Helicobacter Infections / economics
Helicobacter pylori / drug effects
Humans
Lansoprazole
Latin America / epidemiology
Male
Metronidazole / administration & dosage
Proton Pump Inhibitors / administration & dosage*
Randomized Controlled Trials as Topic
Stomach Neoplasms / microbiology*
Stomach Neoplasms / mortality
Stomach Neoplasms / prevention & control*

Substances

2-Pyridinylmethylsulfinylbenzimidazoles
Anti-Bacterial Agents
Drugs, Generic
Proton Pump Inhibitors
Lansoprazole
Metronidazole
Amoxicillin
Clarithromycin